JP2013518902A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518902A5 JP2013518902A5 JP2012552115A JP2012552115A JP2013518902A5 JP 2013518902 A5 JP2013518902 A5 JP 2013518902A5 JP 2012552115 A JP2012552115 A JP 2012552115A JP 2012552115 A JP2012552115 A JP 2012552115A JP 2013518902 A5 JP2013518902 A5 JP 2013518902A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- tetrahydro
- trifluoromethyl
- carbazol
- dichloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 21
- 206010006895 Cachexia Diseases 0.000 claims description 12
- 206010060800 Hot flush Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 8
- 208000027418 Wounds and injury Diseases 0.000 claims description 8
- 208000029078 coronary artery disease Diseases 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 238000002657 hormone replacement therapy Methods 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 8
- 208000033830 Hot Flashes Diseases 0.000 claims description 7
- 206010022489 Insulin Resistance Diseases 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 201000004384 Alopecia Diseases 0.000 claims description 4
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 4
- 206010053567 Coagulopathies Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 206010013883 Dwarfism Diseases 0.000 claims description 4
- 208000005189 Embolism Diseases 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 4
- 208000004930 Fatty Liver Diseases 0.000 claims description 4
- 206010017076 Fracture Diseases 0.000 claims description 4
- 208000036119 Frailty Diseases 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 4
- 206010020112 Hirsutism Diseases 0.000 claims description 4
- 206010024264 Lethargy Diseases 0.000 claims description 4
- 208000026139 Memory disease Diseases 0.000 claims description 4
- 206010027304 Menopausal symptoms Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 208000029725 Metabolic bone disease Diseases 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 208000000112 Myalgia Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 4
- 206010049088 Osteopenia Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 208000027868 Paget disease Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 4
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 4
- 206010039792 Seborrhoea Diseases 0.000 claims description 4
- 208000020221 Short stature Diseases 0.000 claims description 4
- 208000013200 Stress disease Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 206010052428 Wound Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 4
- 206010003549 asthenia Diseases 0.000 claims description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
- 208000015294 blood coagulation disease Diseases 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 208000018631 connective tissue disease Diseases 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 208000010706 fatty liver disease Diseases 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 208000024963 hair loss Diseases 0.000 claims description 4
- 230000003676 hair loss Effects 0.000 claims description 4
- 201000001421 hyperglycemia Diseases 0.000 claims description 4
- 201000001881 impotence Diseases 0.000 claims description 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 4
- 208000000509 infertility Diseases 0.000 claims description 4
- 230000036512 infertility Effects 0.000 claims description 4
- 231100000535 infertility Toxicity 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 208000027202 mammary Paget disease Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 201000006938 muscular dystrophy Diseases 0.000 claims description 4
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 208000028169 periodontal disease Diseases 0.000 claims description 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 4
- 208000001076 sarcopenia Diseases 0.000 claims description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 4
- 229960003604 testosterone Drugs 0.000 claims description 4
- 206010043554 thrombocytopenia Diseases 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 208000018035 Dental disease Diseases 0.000 claims description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 3
- 208000014151 Stomatognathic disease Diseases 0.000 claims description 3
- 208000001435 Thromboembolism Diseases 0.000 claims description 3
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims description 3
- 208000016253 exhaustion Diseases 0.000 claims description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 3
- 201000008980 hyperinsulinism Diseases 0.000 claims description 3
- 208000013465 muscle pain Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 208000020685 sleep-wake disease Diseases 0.000 claims description 3
- 206010048828 underweight Diseases 0.000 claims description 3
- 230000001457 vasomotor Effects 0.000 claims description 3
- 230000004596 appetite loss Effects 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 208000019017 loss of appetite Diseases 0.000 claims description 2
- 235000021266 loss of appetite Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 10
- 229910052731 fluorine Inorganic materials 0.000 claims 10
- 239000011737 fluorine Substances 0.000 claims 10
- 229910052801 chlorine Inorganic materials 0.000 claims 8
- 239000000460 chlorine Substances 0.000 claims 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 7
- 239000000178 monomer Substances 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 5
- 229910052794 bromium Inorganic materials 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- -1 salt compound Chemical class 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 206010051747 multiple endocrine neoplasia Diseases 0.000 claims 2
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- OZXBEIHRSWLQHT-GFCCVEGCSA-N (1r)-6,7-dichloro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C2=C1[C@@](O)(C(F)(F)F)CCC2 OZXBEIHRSWLQHT-GFCCVEGCSA-N 0.000 claims 1
- GLOACQUUNCBWQT-GFCCVEGCSA-N (1r)-6,8-dichloro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=C(Cl)C=C(Cl)C=C2C2=C1[C@@](O)(C(F)(F)F)CCC2 GLOACQUUNCBWQT-GFCCVEGCSA-N 0.000 claims 1
- OZXBEIHRSWLQHT-LBPRGKRZSA-N (1s)-6,7-dichloro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C2=C1[C@](O)(C(F)(F)F)CCC2 OZXBEIHRSWLQHT-LBPRGKRZSA-N 0.000 claims 1
- UYVPMSMQBOHCIJ-UHFFFAOYSA-N 2,4-dichloro-6-(trifluoromethyl)-7,8,9,10-tetrahydro-5h-cyclohepta[b]indol-6-ol Chemical compound FC(F)(F)C1(O)CCCCC2=C1NC1=C(Cl)C=C(Cl)C=C21 UYVPMSMQBOHCIJ-UHFFFAOYSA-N 0.000 claims 1
- VJXGECHHOUASAO-UHFFFAOYSA-N 2-benzyl-5,6-dichloro-9h-carbazol-1-ol Chemical compound C1=CC(C2=C(Cl)C(Cl)=CC=C2N2)=C2C(O)=C1CC1=CC=CC=C1 VJXGECHHOUASAO-UHFFFAOYSA-N 0.000 claims 1
- KPGQCUGJRGDYSE-UHFFFAOYSA-N 2-benzyl-6,7-dichloro-9h-carbazol-1-ol Chemical compound C1=CC(C2=CC(Cl)=C(Cl)C=C2N2)=C2C(O)=C1CC1=CC=CC=C1 KPGQCUGJRGDYSE-UHFFFAOYSA-N 0.000 claims 1
- JWRPBUGOHRYASA-UHFFFAOYSA-N 2-bromo-6,7-dichloro-9h-carbazol-1-ol Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C2=C1C(O)=C(Br)C=C2 JWRPBUGOHRYASA-UHFFFAOYSA-N 0.000 claims 1
- QGJJANJFBJTWCT-UHFFFAOYSA-N 5,6,7-trichloro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC(Cl)=C(Cl)C(Cl)=C2C2=C1C(O)(C(F)(F)F)CCC2 QGJJANJFBJTWCT-UHFFFAOYSA-N 0.000 claims 1
- ZMCLYZWHCWDGQL-UHFFFAOYSA-N 5,6,8-trichloro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=C(Cl)C=C(Cl)C(Cl)=C2C2=C1C(O)(C(F)(F)F)CCC2 ZMCLYZWHCWDGQL-UHFFFAOYSA-N 0.000 claims 1
- BFVQEOVSAUKIEG-UHFFFAOYSA-N 5,6-dichloro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC=C(Cl)C(Cl)=C2C2=C1C(O)(C(F)(F)F)CCC2 BFVQEOVSAUKIEG-UHFFFAOYSA-N 0.000 claims 1
- UYSSSLCWLNMVTN-UHFFFAOYSA-N 5,6-dichloro-2-fluoro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC=C(Cl)C(Cl)=C2C2=C1C(O)(C(F)(F)F)C(F)CC2 UYSSSLCWLNMVTN-UHFFFAOYSA-N 0.000 claims 1
- FFLPEQIVXOVSGF-UHFFFAOYSA-N 5,6-dichloro-2-methyl-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound C1=C(Cl)C(Cl)=C2C(CCC(C3(O)C(F)(F)F)C)=C3NC2=C1 FFLPEQIVXOVSGF-UHFFFAOYSA-N 0.000 claims 1
- YGHNPEADFBWJMM-UHFFFAOYSA-N 5,6-dichloro-9h-carbazol-1-ol Chemical compound N1C2=CC=C(Cl)C(Cl)=C2C2=C1C(O)=CC=C2 YGHNPEADFBWJMM-UHFFFAOYSA-N 0.000 claims 1
- KKCKHZUAVYBTFB-UHFFFAOYSA-N 5,7-dichloro-3-(trifluoromethyl)-2,4-dihydro-1h-cyclopenta[b]indol-3-ol Chemical compound N1C2=C(Cl)C=C(Cl)C=C2C2=C1C(O)(C(F)(F)F)CC2 KKCKHZUAVYBTFB-UHFFFAOYSA-N 0.000 claims 1
- MOOANAHHINSSPK-UHFFFAOYSA-N 5-chloro-6-fluoro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC=C(F)C(Cl)=C2C2=C1C(O)(C(F)(F)F)CCC2 MOOANAHHINSSPK-UHFFFAOYSA-N 0.000 claims 1
- QBSXZCAAQUKLIN-UHFFFAOYSA-N 6,7-dichloro-1-(1,1,2,2,2-pentafluoroethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C2=C1C(O)(C(F)(F)C(F)(F)F)CCC2 QBSXZCAAQUKLIN-UHFFFAOYSA-N 0.000 claims 1
- OZXBEIHRSWLQHT-UHFFFAOYSA-N 6,7-dichloro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C2=C1C(O)(C(F)(F)F)CCC2 OZXBEIHRSWLQHT-UHFFFAOYSA-N 0.000 claims 1
- FFQXLJXMHWLJMQ-UHFFFAOYSA-N 6,7-dichloro-1-methyl-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C2=C1C(C)(O)CCC2 FFQXLJXMHWLJMQ-UHFFFAOYSA-N 0.000 claims 1
- VSYXPEOPYUZLMW-UHFFFAOYSA-N 6,7-dichloro-2,2-difluoro-1-(trifluoromethyl)-4,9-dihydro-3h-carbazol-1-ol Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C2=C1C(C(F)(F)F)(O)C(F)(F)CC2 VSYXPEOPYUZLMW-UHFFFAOYSA-N 0.000 claims 1
- KGYITEFEOAWUCU-UHFFFAOYSA-N 6,7-dichloro-2-fluoro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C2=C1C(O)(C(F)(F)F)C(F)CC2 KGYITEFEOAWUCU-UHFFFAOYSA-N 0.000 claims 1
- BQKIMLLLBKPXOU-UHFFFAOYSA-N 6,7-dichloro-2-methyl-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound ClC1=C(Cl)C=C2C(CCC(C3(O)C(F)(F)F)C)=C3NC2=C1 BQKIMLLLBKPXOU-UHFFFAOYSA-N 0.000 claims 1
- KATFAQVKRVSADT-UHFFFAOYSA-N 6,7-dichloro-3-(trifluoromethyl)-2,4-dihydro-1h-cyclopenta[b]indol-3-ol Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C2=C1C(O)(C(F)(F)F)CC2 KATFAQVKRVSADT-UHFFFAOYSA-N 0.000 claims 1
- GLOACQUUNCBWQT-UHFFFAOYSA-N 6,8-dichloro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=C(Cl)C=C(Cl)C=C2C2=C1C(O)(C(F)(F)F)CCC2 GLOACQUUNCBWQT-UHFFFAOYSA-N 0.000 claims 1
- ZNQUFMFGFSMGLK-UHFFFAOYSA-N 6,8-dichloro-2,2-difluoro-1-(trifluoromethyl)-4,9-dihydro-3h-carbazol-1-ol Chemical compound N1C2=C(Cl)C=C(Cl)C=C2C2=C1C(C(F)(F)F)(O)C(F)(F)CC2 ZNQUFMFGFSMGLK-UHFFFAOYSA-N 0.000 claims 1
- AQPPCKBTCIQHBJ-UHFFFAOYSA-N 6-chloro-8-fluoro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=C(F)C=C(Cl)C=C2C2=C1C(O)(C(F)(F)F)CCC2 AQPPCKBTCIQHBJ-UHFFFAOYSA-N 0.000 claims 1
- VAQQPYHQQCGPMC-UHFFFAOYSA-N 7,8-dichloro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=C(Cl)C(Cl)=CC=C2C2=C1C(O)(C(F)(F)F)CCC2 VAQQPYHQQCGPMC-UHFFFAOYSA-N 0.000 claims 1
- HVDRWCKUQMRDGT-UHFFFAOYSA-N 7,8-dichloro-3-(trifluoromethyl)-2,4-dihydro-1h-cyclopenta[b]indol-3-ol Chemical compound N1C2=CC=C(Cl)C(Cl)=C2C2=C1C(O)(C(F)(F)F)CC2 HVDRWCKUQMRDGT-UHFFFAOYSA-N 0.000 claims 1
- RKCMFKAWCUGATK-UHFFFAOYSA-N 7-chloro-6-fluoro-1-(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=CC(Cl)=C(F)C=C2C2=C1C(O)(C(F)(F)F)CCC2 RKCMFKAWCUGATK-UHFFFAOYSA-N 0.000 claims 1
- FDRMTRSYPSJWQJ-UHFFFAOYSA-N 8-chloro-6-fluoro-1,2-bis(trifluoromethyl)-2,3,4,9-tetrahydrocarbazol-1-ol Chemical compound N1C2=C(Cl)C=C(F)C=C2C2=C1C(O)(C(F)(F)F)C(C(F)(F)F)CC2 FDRMTRSYPSJWQJ-UHFFFAOYSA-N 0.000 claims 1
- UDUFALSRKCWTRJ-UHFFFAOYSA-N 8-hydroxy-1,8-bis(trifluoromethyl)-5,6,7,9-tetrahydrocarbazole-3-carbonitrile Chemical compound N1C2=C(C(F)(F)F)C=C(C#N)C=C2C2=C1C(O)(C(F)(F)F)CCC2 UDUFALSRKCWTRJ-UHFFFAOYSA-N 0.000 claims 1
- DZMHVXDYRBLHFR-UHFFFAOYSA-N 8-hydroxy-8-(trifluoromethyl)-5,6,7,9-tetrahydrocarbazole-3-carbonitrile Chemical compound N1C2=CC=C(C#N)C=C2C2=C1C(O)(C(F)(F)F)CCC2 DZMHVXDYRBLHFR-UHFFFAOYSA-N 0.000 claims 1
- IICQMRDIWOGNKM-UHFFFAOYSA-N 8-hydroxy-8-methyl-5,6,7,9-tetrahydrocarbazole-3-carbonitrile Chemical compound N1C2=CC=C(C#N)C=C2C2=C1C(C)(O)CCC2 IICQMRDIWOGNKM-UHFFFAOYSA-N 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 102000001307 androgen receptors Human genes 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000009852 coagulant defect Effects 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 201000003073 testicular leukemia Diseases 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 description 3
- 238000000034 method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000036487 Arthropathies Diseases 0.000 description 1
- 0 CCC=C(C(CC(C)(C)*CC(C1[Rh])O)=C1N1)C1=CC=C Chemical compound CCC=C(C(CC(C)(C)*CC(C1[Rh])O)=C1N1)C1=CC=C 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30149210P | 2010-02-04 | 2010-02-04 | |
| US61/301,492 | 2010-02-04 | ||
| PCT/US2011/023768 WO2011097496A1 (en) | 2010-02-04 | 2011-02-04 | Selective androgen receptor modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016035296A Division JP2016138118A (ja) | 2010-02-04 | 2016-02-26 | 選択的アンドロゲン受容体モジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518902A JP2013518902A (ja) | 2013-05-23 |
| JP2013518902A5 true JP2013518902A5 (https=) | 2015-05-28 |
| JP5964756B2 JP5964756B2 (ja) | 2016-08-03 |
Family
ID=44355809
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552115A Expired - Fee Related JP5964756B2 (ja) | 2010-02-04 | 2011-02-04 | 選択的アンドロゲン受容体モジュレーター |
| JP2016035296A Pending JP2016138118A (ja) | 2010-02-04 | 2016-02-26 | 選択的アンドロゲン受容体モジュレーター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016035296A Pending JP2016138118A (ja) | 2010-02-04 | 2016-02-26 | 選択的アンドロゲン受容体モジュレーター |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8987319B2 (https=) |
| EP (1) | EP2531029B1 (https=) |
| JP (2) | JP5964756B2 (https=) |
| AU (1) | AU2011212813B2 (https=) |
| BR (1) | BR112012019551A2 (https=) |
| CA (1) | CA2788907A1 (https=) |
| MX (1) | MX338831B (https=) |
| WO (1) | WO2011097496A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4464384A3 (en) | 2007-08-17 | 2025-01-08 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| MX338831B (es) | 2010-02-04 | 2016-05-03 | Radius Health Inc | Moduladores selectivos de receptores de androgenos. |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| EP2568806B1 (en) | 2010-05-12 | 2016-05-11 | Radius Health, Inc. | Therapeutic regimens |
| US9133182B2 (en) | 2010-09-28 | 2015-09-15 | Radius Health, Inc. | Selective androgen receptor modulators |
| CN103172643B (zh) * | 2011-12-26 | 2016-03-02 | 中国医学科学院药物研究所 | 黄皮咔唑生物碱及其制备方法和其药物组合物与用途 |
| BR112015011118B1 (pt) | 2012-11-15 | 2022-12-13 | Endocyte, Inc | Conjugado; composição farmacêutica; e uso de um conjugado |
| LT4095130T (lt) | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| BR112016010927A2 (pt) | 2013-11-14 | 2017-08-08 | Endocyte Inc | Conjugado de fórmula |
| US9682960B2 (en) | 2013-12-19 | 2017-06-20 | Endorecherche, Inc. | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety |
| FI3834824T3 (fi) | 2014-03-28 | 2025-12-05 | Univ Duke | Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| JP6757037B2 (ja) * | 2016-02-15 | 2020-09-16 | 学校法人近畿大学 | ストレス評価方法 |
| LT3474841T (lt) | 2016-06-22 | 2022-06-10 | Ellipses Pharma Ltd | Ar+ krūties vėžio gydymo būdai |
| KR102707399B1 (ko) | 2017-01-05 | 2024-09-13 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
| US12208102B2 (en) | 2018-04-17 | 2025-01-28 | Endocyte, Inc. | Methods of treating cancer |
| IL279853B2 (en) | 2018-07-04 | 2025-01-01 | Radius Pharmaceuticals Inc | Polymorphic forms of RAD 1901-2HCL |
| CN109239214B (zh) * | 2018-09-19 | 2020-01-31 | 珠海润都制药股份有限公司 | 一种沙库比曲钠中沙库比曲异构体检验方法 |
| CN113348163B (zh) | 2019-02-12 | 2024-10-08 | 雷迪厄斯制药公司 | 方法和化合物 |
| CN114096264B (zh) | 2019-05-20 | 2025-03-14 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| EP4434968A4 (en) * | 2021-11-19 | 2025-10-22 | Nain Biotech Hangzhou Co Ltd | TETRAHYDROCARBAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1547758A (en) | 1975-07-29 | 1979-06-27 | Shell Int Research | Herbicidal composition |
| JPH01261381A (ja) | 1988-04-12 | 1989-10-18 | Nippon Soda Co Ltd | オキサ（チア）ジアゾール誘導体、その製造方法及び殺ダニ剤 |
| US5411981A (en) | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
| FR2693461B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| GB9310635D0 (en) * | 1993-05-21 | 1993-07-07 | Glaxo Group Ltd | Chemical compounds |
| UA51652C2 (uk) | 1995-06-08 | 2002-12-16 | Новартіс Аг | Спосіб гідрування імінів |
| JP2000513362A (ja) | 1996-06-27 | 2000-10-10 | リガンド・ファーマスーティカルス・インコーポレーテッド | アンドロゲン受容体モジュレーター化合物及び方法 |
| US20090264534A1 (en) | 1996-11-27 | 2009-10-22 | Dalton James T | Selective androgen receptor modulators |
| FR2770842B1 (fr) | 1997-11-13 | 1999-12-17 | Oreal | Nouveaux composes derives de n-aryl 2-hydroxy alkylamides |
| US6159959A (en) * | 1999-05-06 | 2000-12-12 | American Home Products Corporation | Combined estrogen and antiestrogen therapy |
| BR0111298A (pt) | 2000-06-28 | 2005-05-10 | Bristol Myers Squibb Co | Moduladores seletivos dos receptores de andrógenos e métodos para identificação, projeto e uso dos mesmos |
| EP1401801B1 (en) | 2000-08-24 | 2006-11-02 | The University Of Tennessee Research Corporation | Selective androgen receptor modulators and methods of use thereof |
| WO2003011824A1 (en) | 2001-07-31 | 2003-02-13 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
| MXPA04007870A (es) | 2002-02-15 | 2005-06-20 | Endorech Inc | Derivados de bifenilo y su uso como agentes antiandrogenicos. |
| US7772433B2 (en) | 2002-02-28 | 2010-08-10 | University Of Tennessee Research Foundation | SARMS and method of use thereof |
| TW200407324A (en) | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
| AU2003248052A1 (en) | 2002-07-12 | 2004-02-02 | Yamanouchi Pharmaceutical Co., Ltd. | N-phenyl-(2r,5s)dimethylpiperadine derivative |
| BR0313405A (pt) | 2002-08-12 | 2005-07-12 | Takeda Pharmaceutical | Compostos, métodos para preparar um composto e para prevenir e/ou tratar câncer, prodroga, medicamento, modulador do receptor de androgênio, agente para prevenir e/ou tratar hipogonadismo ou pertubação climatérica masculina, osteoporose e câncer, e, uso de um composto |
| EP1581217A4 (en) | 2002-11-01 | 2007-07-11 | Merck & Co Inc | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ANDROGENIC RECEPTORS |
| UA79504C2 (en) | 2002-11-07 | 2007-06-25 | Organon Nv | Indols for treating diseases associated with androgen receptors |
| US7632858B2 (en) | 2002-11-15 | 2009-12-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
| EP1603858A2 (en) | 2003-03-11 | 2005-12-14 | NeuroSearch A/S | Kcnq channel modulating compounds and their pharmaceutical use |
| US20060142387A1 (en) | 2003-06-10 | 2006-06-29 | Rodolfo Cadilla | Chemical compounds |
| JP2007500245A (ja) | 2003-06-10 | 2007-01-11 | スミスクライン ビーチャム コーポレーション | 化合物 |
| FI20030958A0 (fi) | 2003-06-27 | 2003-06-27 | Orion Corp | Uusia yhdisteitä |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| AU2004272007B2 (en) | 2003-09-10 | 2009-05-28 | Merck Sharp & Dohme Corp. | 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
| US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| GB0324551D0 (en) | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
| US7256208B2 (en) | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
| CA2545048A1 (en) | 2003-11-20 | 2005-06-02 | Warner-Lambert Company Llc | Androgen receptor modulators |
| WO2005060956A1 (en) | 2003-12-12 | 2005-07-07 | University Of Maryland, Baltimore | IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN |
| KR101536701B1 (ko) | 2004-01-07 | 2015-07-14 | 앙도르쉐르슈 인코포레이티드 | 헬릭스 12 배향형 스테로이드계 약학 제품 |
| US20050182105A1 (en) | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
| US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
| JP4805909B2 (ja) | 2004-03-03 | 2011-11-02 | スミスクライン ビーチャム コーポレーション | 選択的アンドロゲン受容体モジュレーターとしてのアニリン誘導体 |
| US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
| US7388027B2 (en) | 2004-03-04 | 2008-06-17 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
| US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| GB0405033D0 (en) | 2004-03-05 | 2004-04-07 | Karobio Ab | Novel pharmaceutical compositions |
| US8519158B2 (en) * | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| JP2007223901A (ja) | 2004-03-24 | 2007-09-06 | Takeda Chem Ind Ltd | 複素環化合物およびその用途 |
| CA2562132A1 (en) | 2004-04-08 | 2005-10-27 | Merck & Co., Inc. | 17 beta-acetamide-4-azasteroids as androgen receptor modulators |
| TW200602317A (en) | 2004-04-23 | 2006-01-16 | Akzo Nobel Nv | Novel androgens |
| CN1980917B (zh) | 2004-05-03 | 2014-02-12 | 詹森药业有限公司 | 作为选择性雄激素受体调节剂（sarms）的新的吲哚衍生物 |
| CN1980891B (zh) * | 2004-05-03 | 2011-03-09 | 詹森药业有限公司 | 作为选择性雄激素受体调节剂(sarms)的吲哚、苯并呋喃和苯并噻吩衍生物 |
| EP1747193A1 (en) | 2004-05-11 | 2007-01-31 | Pfizer Products Incorporated | Benzonitrile derivatives to treat musculoskeletal frailty |
| CA2566942A1 (en) | 2004-05-17 | 2005-12-08 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
| US20080119456A1 (en) | 2004-05-29 | 2008-05-22 | Trond Ulven | Substituted Thiazoleacetic Acid as Crth2 Ligands |
| ATE552235T1 (de) | 2004-06-07 | 2012-04-15 | Univ Tennessee Res Foundation | Selektive androgen-rezeptor-modulator und anwendungsverfahren dafür |
| EP1791821B1 (en) | 2004-09-10 | 2013-06-05 | Janssen Pharmaceutica NV | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms) |
| ATE514700T1 (de) | 2004-09-20 | 2011-07-15 | Janssen Pharmaceutica Nv | Neues tetrazyklisches heteroatom mit als sexualsteroidhormon-rezeptormodulatoren geeigneten derivaten |
| EP1805147B1 (en) | 2004-09-30 | 2014-08-13 | Janssen Pharmaceutica NV | Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) |
| US8143425B2 (en) | 2004-10-12 | 2012-03-27 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| EP1809275A1 (en) | 2004-10-13 | 2007-07-25 | Smithkline Beecham Corporation | Chemical compounds |
| JP2008518968A (ja) | 2004-10-29 | 2008-06-05 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体モジュレーターとしてのｎ−（ピリジン−３−イル）−２−フェニルブタンアミド |
| CN104803916B (zh) | 2004-11-16 | 2017-08-11 | 詹森药业有限公司 | 用作选择性雄激素受体调节剂(sarms)的杂环衍生物 |
| US8143257B2 (en) * | 2004-11-23 | 2012-03-27 | Ptc Therapeutics, Inc. | Substituted phenols as active agents inhibiting VEGF production |
| NZ555974A (en) | 2005-01-10 | 2010-11-26 | Acadia Pharm Inc | Aminophenyl derivatives as selective androgen receptor modulators |
| WO2006113552A2 (en) | 2005-04-15 | 2006-10-26 | Smithkline Beecham Corporation | Cyanoarylamines |
| DK1891038T3 (da) | 2005-05-13 | 2009-01-19 | Lilly Co Eli | Substituerede n-arylpyrrolidiner som selektive androgenreceptormodulatorer |
| EP1888512A2 (en) | 2005-06-06 | 2008-02-20 | Smithkline Beecham Corporation | Chemical compounds |
| US7829589B2 (en) | 2005-06-10 | 2010-11-09 | Elixir Pharmaceuticals, Inc. | Sulfonamide compounds and uses thereof |
| US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
| CN101203491A (zh) | 2005-06-24 | 2008-06-18 | 伊莱利利公司 | 可用作雄激素受体调节剂的四氢咔唑衍生物（sarm） |
| WO2007005887A2 (en) | 2005-07-01 | 2007-01-11 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds, compositions and uses thereof |
| EP1911743B8 (en) | 2005-08-01 | 2013-01-16 | Takeda Pharmaceutical Company Limited | Cyclic amine compound |
| JP2008303145A (ja) | 2005-09-22 | 2008-12-18 | Takeda Chem Ind Ltd | Ｇｒｋ阻害剤からなる強心薬 |
| US7776859B2 (en) | 2005-10-14 | 2010-08-17 | Bristol-Myers Squibb Company | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function |
| TW200730505A (en) | 2005-12-07 | 2007-08-16 | Merck & Co Inc | Polymorphs of an androgen receptor modulator |
| ES2402305T3 (es) | 2006-01-24 | 2013-04-30 | Janssen Pharmaceutica N.V. | Benzimidazolas 2-sustituidas nuevas como moduladores del receptor de andrógeno selectivo (SARMS) |
| CA2642598C (en) | 2006-03-03 | 2014-05-27 | Orion Corporation | Selective androgen receptor modulators |
| PT2038252T (pt) | 2006-07-12 | 2016-12-16 | Univ Tennessee Res Found | Acilanilidos substituidos e métodos de utilização dos mesmos |
| CA2658098A1 (en) | 2006-07-19 | 2008-01-24 | Osurf | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
| CN101528214B (zh) | 2006-08-24 | 2013-06-05 | 田纳西大学研究基金会 | 取代的n-酰基苯胺及其使用方法 |
| ES2452343T3 (es) | 2006-09-29 | 2014-04-01 | Glaxosmithkline Llc | Compuestos de indol sustituidos |
| WO2008044033A1 (en) | 2006-10-11 | 2008-04-17 | Astrazeneca Ab | Amide derivatives |
| UA98777C2 (en) | 2006-11-20 | 2012-06-25 | Эли Лилли Энд Компани | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators |
| WO2008121602A1 (en) | 2007-03-29 | 2008-10-09 | Smithkline Beecham Corporation | Chemical compounds |
| WO2008124000A2 (en) | 2007-04-02 | 2008-10-16 | Ligand Pharmaceuticals Incorporated | Thiazole derivatives as androgen receptor modulator compounds |
| US9284345B2 (en) | 2007-04-12 | 2016-03-15 | Endorecherche, Inc. | 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators |
| WO2008128100A1 (en) | 2007-04-13 | 2008-10-23 | The Regents Of The University Of California | Small-molecule inhibitors of the androgen receptor |
| PL2176220T3 (pl) | 2007-08-07 | 2013-08-30 | Takeda Pharmaceuticals Co | Pochodne pirolidyn-2-onu jako modulatory receptora androgenowego |
| WO2009065600A2 (en) | 2007-11-21 | 2009-05-28 | Technische Universität Dresden | Means for treating myosin-related diseases |
| KR101595238B1 (ko) | 2007-12-21 | 2016-02-18 | 리간드 파마슈티칼스 인코포레이티드 | 선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도 |
| BRPI0821676A2 (pt) | 2007-12-21 | 2015-06-16 | Astrazeneca Ab | Composto, composição farmacêutica, e, processo para a preparação dos compostos. |
| ES2488990T3 (es) | 2008-02-22 | 2014-09-01 | Radius Health, Inc. | Moduladores selectivos del receptor de andrógenos |
| US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
| WO2009133861A1 (ja) | 2008-04-28 | 2009-11-05 | 武田薬品工業株式会社 | 環状アミン化合物 |
| BRPI0912394A2 (pt) | 2008-05-16 | 2016-07-26 | Lilly Co Eli | moduladores do receptor de androgênio à base de tetra-hidrociclopenta[b]indol |
| WO2010118287A1 (en) | 2009-04-10 | 2010-10-14 | Radius Health, Inc. | Selective androgen receptor modulators |
| MX338831B (es) | 2010-02-04 | 2016-05-03 | Radius Health Inc | Moduladores selectivos de receptores de androgenos. |
| US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| US9133182B2 (en) | 2010-09-28 | 2015-09-15 | Radius Health, Inc. | Selective androgen receptor modulators |
-
2011
- 2011-02-04 MX MX2012008995A patent/MX338831B/es active IP Right Grant
- 2011-02-04 AU AU2011212813A patent/AU2011212813B2/en not_active Ceased
- 2011-02-04 JP JP2012552115A patent/JP5964756B2/ja not_active Expired - Fee Related
- 2011-02-04 US US13/576,754 patent/US8987319B2/en not_active Expired - Fee Related
- 2011-02-04 WO PCT/US2011/023768 patent/WO2011097496A1/en not_active Ceased
- 2011-02-04 CA CA2788907A patent/CA2788907A1/en not_active Abandoned
- 2011-02-04 BR BR112012019551A patent/BR112012019551A2/pt not_active IP Right Cessation
- 2011-02-04 EP EP11740437.6A patent/EP2531029B1/en not_active Not-in-force
-
2015
- 2015-03-23 US US14/665,849 patent/US20150266821A1/en not_active Abandoned
-
2016
- 2016-02-26 JP JP2016035296A patent/JP2016138118A/ja active Pending
- 2016-11-07 US US15/330,845 patent/US20170121285A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518902A5 (https=) | ||
| JP5301469B2 (ja) | Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体 | |
| JP6469092B2 (ja) | イミダゾリジンジオン化合物及び薬物組成物 | |
| JP2019524883A5 (https=) | ||
| JP2016053078A (ja) | がん及び非新生物性状態の治療方法 | |
| RU2008149242A (ru) | Малеатный сокристалл azd1152 | |
| RU2689315C2 (ru) | Соль гетероциклического соединения, замещенного галогеном | |
| JP2014193925A5 (https=) | ||
| AU2015341177B2 (en) | Six-membered ring benzo derivatives as DPP-4 inhibitor and use thereof | |
| JP2011514376A (ja) | 新規の１，２，４−トリアゾール誘導体およびそれらの製造方法 | |
| TWI761471B (zh) | Atf3誘導化合物 | |
| RU2013120556A (ru) | 1,2-гидрокси-2-оксо-хинолин-3-карбоксанилиды в качестве активаторов ahr | |
| BRPI0921097B1 (pt) | composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto | |
| TW202313592A (zh) | 喹啉胺類化合物、其製備方法及其在醫藥上的應用 | |
| JPWO2018216640A1 (ja) | Ｅｐ４アンタゴニスト | |
| CN103717594B (zh) | 包含二羟基取代基的trpv1拮抗剂及其用途 | |
| JP2017536362A5 (https=) | ||
| HUE025111T2 (en) | 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors | |
| CN1156454A (zh) | N-取代的3-氮杂双环[3，2，0]庚烷衍生物及其制备方法和应用 | |
| RU2543484C2 (ru) | Пиразины для использования в качестве модуляторов дельта-опиоидных рецепторов | |
| WO2001014382A1 (en) | Analgesics containing as the active ingredient quaternary ammonium salt derivatives of morphinan | |
| CA2973746A1 (en) | Prevention or treatment of uratic or gouty diseases | |
| CA2584757A1 (en) | Halogen substituted benzodiazepine derivatives | |
| TWI909603B (zh) | 用於預防或治療癌症或腫瘤之新穎化合物及包含該化合物的醫藥組成物 | |
| CN1341021A (zh) | 多环噻唑体系用于制备预防或治疗肥胖的药物的用途 |